Patient-derived Breast Cancer Cell Line Characterization

All cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD). WHIM 3 is a breast cancer cell line that was derived from a patient-derived xenograft.^{24 (link)} WHIM 3 was provided by the HAMLET core at WUSM. All cell lines were maintained in RPMI or DMEM Supplemented with 10% FBS and antibiotics (GIBCO BRL, Grand Island, NY). MCF-10A cells were grown in MEGM Mammary Epithelial Cell Growth Medium (Lonza, Allendale, NJ) Supplemented with 5% Horse serum. Recombinant EGF, TGFβ and TNFα were purchased from R&D Systems (Minneapolis, MN). The MAP kinase inhibitors U0126, PD98059, SB203580, SP600125, and LY29004 were purchased from Selleck Chemicals (Houston, TX).